There’s another $665 million in potential milestones and a royalty tied to the deal, which focuses on OSE-230, billed as a potentially first-in-class activator of ChemR23, a G-protein coupled ...

OKYO Pharma has filed a Fast Track designation application with the Food and Drug Administration (FDA) for urcosimod in the treatment of neuropathic ...